Rösler M, Frey U
Arbeitsgruppe Gerontopsychiatrie, Universitätskliniken des Saarlandes, Homburg, Germany.
Fortschr Neurol Psychiatr. 2002 Feb;70(2):78-83. doi: 10.1055/s-2002-19920.
The treatment of the cognitive deficits has been the major focus in patients with Alzheimer's disease (DAT) so far. Recently there is increasing interest in Behavioral and Psychological Symptoms of Dementia (BPSD), which can place much burden on DAT patients and their caregivers. With the introduction of Acetylcholinesterase Inhibitors (AChEI) of the second generation the therapeutic armament has been extended. The clinical evaluation of AChEI has found growing evidence that these compounds do not only improve cognitive abilities and activities of daily living (ADL), but also BPSD. The given data regarding the three AChEI available on the market allow the conclusion that there is a general improvement in BPSD. Beside these particularly positive effects on hallucinations, mood symptoms, aggressiveness, and agitation seem possible but need further clarification.
到目前为止，认知缺陷的治疗一直是阿尔茨海默病（DAT）患者的主要关注点。最近，人们对痴呆症的行为和心理症状（BPSD）越来越感兴趣，这些症状会给DAT患者及其护理人员带来很大负担。随着第二代乙酰胆碱酯酶抑制剂（AChEI）的引入，治疗手段得到了扩展。对AChEI的临床评估发现，越来越多的证据表明，这些化合物不仅能改善认知能力和日常生活活动（ADL），还能改善BPSD。关于市场上现有的三种AChEI的给定数据表明，BPSD总体上有所改善。除了对幻觉有特别积极的影响外，情绪症状、攻击性和激越似乎也有可能改善，但需要进一步阐明。
